Abbott gains more rights to Sonus agent
Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the
Sonus Pharmaceuticals of Bothell, WA, has granted U.S. marketingpartner Abbott Laboratories licensing rights to its EchoGen ultrasoundcontrast agent in all international territories outside Japanand nine other Asia-Pacific countries. In exchange for the internationalrights, Abbott, of Abbott Park, IL, has agreed to make $34.6 millionin license and milestone payments, some of which will be creditedagainst future royalties.
Sonus and Abbott in May reached a pact covering EchoGen salesin the U.S. (SCAN 5/22/96). With this latest deal, Abbott gainsEchoGen marketing rights to additional territories, includingEurope, the rights to which Sonus regained from French contrastfirm Guerbet earlier this year (SCAN 9/11/96). Daiichi Pharmaceuticalhas marketing rights in Pacific Rim countries.
Sonus has filed a new drug application for EchoGen with theFood and Drug Administration and plans to file for European regulatoryapproval of the product by the end of this year.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
